Lancet Gastroenterology & Hepatology

Article	Citations
Research in Brief	1484
EASL Congress 2024	514
GORD: pain, PPIs, and preciseness	472
Research in Brief	432
Aldafermin in non-alcoholic steatohepatitis: a cautionary tale for trial design	427
Correction to Lancet Gastroenterol Hepatol 2017; 2: 103–11	415
Lucky: Learning to Live Again	386
Viral hepatitis: time for action	312
The role of ERAS in robotic pancreaticoduodenectomy – Authors' reply	308
Treatment withdrawal in Crohn's disease: slowly becoming clearer	305
Trends in alcohol-specific deaths in the UK and industry responses	271
Immune checkpoint inhibitors in colorectal cancer: dream and reality	271
Closing the gender gap in gastroenterology leadership: the need for effective and comprehensive allyship	257
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension	212
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study	212
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma	210
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled	210
Correction to Lancet Gastroenterol Hepatol 2025; 10: 418–30	204
Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic	204
Nationwide practice change after early termination of a randomised trial of laparoscopic pancreatoduodenectomy	203
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium	201
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives	199
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept t	196
A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial	179
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial	178

Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial	164
Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis	160
International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement	153
Global multi-stakeholder endorsement of the MAFLD definition	151
Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study	146
ACG 2024	141
Rare cause of dysphagia in a young woman	139
Water and sanitation for all	139
Bringing organ preservation closer for selected patients with rectal cancer	132
The potential of ctDNA in locoregional therapies for colorectal cancer	128
Addressing the rise of early-onset colorectal cancer	127
Management of portal vein thrombosis in cirrhosis	126
U-ACTIVATE long-term efficacy and safety outcomes for upadacitinib in ulcerative colitis	124
Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere	122
The pitfalls and promises of scoping reviews in gastroenterology literature – Authors’ reply	122
The present and future of gastroenterology and hepatology: an international SWOT analysis (the GASTROSWOT project)	117
Availability of point-of-care HBV tests in resource-limited settings	115
Endoscopist deskilling: an unintended consequence of AI-assisted colonoscopy?	113
Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial	111
Sex and gender in inflammatory bowel disease outcomes and research	109
Resmetirom for NASH: balancing promise and prudence	108
Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review	103
All roads lead to the gut–brain microbiome network	102
Local and systemic therapy in liver cancer: the quest for synergy	100
Research in Brief	100
Idiopathic gastroparesis consensus misses the patient's voice	99
Combined tumour-infiltrating lymphocytes and microsatellite instability status as prognostic markers in colorectal cancer – Authors' reply	98
Has the time come for a systematic top-down approach in Crohn's disease?	97
Uptick of food allergies in recent years—real or epiphenomenon?	94
Addressing inequities in access to care among Indigenous peoples with chronic hepatitis C in Alberta, Canada	94
Correction to Lancet Gastroenterol Hepatol 2022; 7: 627–47	94
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial	94
Long-term VEDOKIDS results: implications for practice and research	94
Britta Siegmund: answering the big questions in IBD	93
Prevalence of hepatitis C virus seropositivity and active infection in a Rohingya refugee population in Cox's Bazar camps, Bangladesh: a cross-sectional study	93
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study	93
Management of malignant bowel obstruction – Authors' reply	92
Research in Brief	91
The Year My Life Went Down the Toilet	90
Robotic versus laparoscopic surgery for middle and low rectal cancer	90
Lifting the minority tax in gastroenterology and hepatology	87
Closing the gender gap: building a successful career and leadership in research as a female gastroenterologist	86
Hypovolaemic phlebotomy for hepatic resection	82
Unifying the approach to tackling inequalities in liver health: learning from working with underserved populations	80
Managing inflammatory bowel disease: what to do when the best is unaffordable?	79
Dangerous Medicine	78
Research in Brief	78
A women-focused matrix mentorship programme in gastroenterology	78
CEND-1: a game changer for pancreatic cancer chemotherapy?	76
An unusual complication after a variceal glue injection	74

The growth of faecal microbiota transplantation in the UK: time for a registry?	73
Comprehensive screening for superficial oesophageal squamous cell carcinoma and precancerous lesions	72
Shitbag: the story of a diagnosis	71
Machine learning-based automated sponge cytology for screening of oesophageal squamous cell carcinoma and adenocarcinoma of the oesophagogastric junction: a nationwide, multicohort, prospective study	71
18th Congress of the European Crohn's and Colitis Organisation	71
Practicalities accessing precision medicine in biliary tract cancer	71
Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED	71
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial	71
Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial	70
Long-term safety of faecal microbiota transplantation for gastrointestinal diseases in China	70
Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities	69
Urgent action needed to achieve viral hepatitis elimination	67
Another arrow in the NASH quiver?	66
Scientific and medical evidence informing expansion of hepatitis B treatment guidelines	66
Early antiviral therapy in adults with moderate to highly viraemic chronic hepatitis B	64
Primary biliary cholangitis and the narrowing gap towards optimal disease control	63
Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment de	62
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial	61
Research in Brief	61
Correction to Lancet Gastroenterol Hepatol 2021; 6: 781	61
The world is failing on hunger	60
COP27 Climate Change Conference: urgent action needed for Africa and the world	60
Bringing dietary therapy for eosinophilic oesophagitis under scientific scrutiny	60
Compensation advised for UK victims of contaminated blood scandal	60
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis	57
Immune-checkpoint blockade in surgical management of gastric or gastro-oesophageal junction adenocarcinoma	57
Primary intestinal lymphangiectasia	57
Research in brief	56
Induction of microRNA-124 as a novel therapeutic concept in ulcerative colitis	55
Bowel cancer prevention: are we missing an opportunity?	54
Management of portal vein thrombosis in cirrhosis – Authors' reply	54
Correction to Lancet Gastroenterol Hepatol 2023; 8: 908–18	53
Combining systemic and local therapies for hepatocellular carcinoma	53
Simplifying HCV treatment: a pathway to elimination and model for delivering health care to vulnerable populations	53
Patient and public health perspectives to inform expansion of hepatitis B treatment guidelines	52
Alcohol and health: time for Europe to sober up	51
The top 10 research priorities for inflammatory bowel disease in children and young adults: results of a James Lind Alliance Priority Setting Partnership	50
Clinical management of liver cyst infections: an international, modified Delphi-based clinical decision framework	50
Community pathways for the early detection and risk stratification of chronic liver disease: a narrative systematic review	48
The problem of antimicrobial resistance in chronic liver disease	48
Laparoscopic versus open pancreatoduodenectomy for pancreatic or peri-ampullary tumours	48
Hypovolaemic phlebotomy in patients undergoing hepatic resection at higher risk of blood loss (PRICE-2): a randomised controlled trial	48
Development and validation of the Gender-Equity Model for Liver Allocation (GEMA) to prioritise candidates for liver transplantation: a cohort study	47
Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study	47
PANTS extension study: how best to use anti-TNF drugs in Crohn's disease	47
Increasing burden of colorectal cancer in China	47
The intestinal barrier: a pivotal role in health, inflammation, and cancer	47
Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease	47
DEI in gastroenterology and hepatology	46
Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection	46
Research in Brief	46
The British Association for the Study of the Liver commitment to equality, diversity, and inclusivity	46
Peroral endoscopic myotomy versus pneumatic dilation for achalasia	46
Does filgotinib work for Crohn's disease?	44
Lessons and open questions in borderline resectable pancreatic cancer	44
The costs of inadequate toilet coverage in the Philippines	44
HIV pre-exposure prophylaxis as an entry point to the elimination of hepatitis B virus	43
Cost of colorectal cancer care: sufficient to inform cancer policy?	43
Gastroenterology training in Africa: an assessment of curriculum and perception	43
Early-onset colorectal cancer: Hollyoaks tackles taboos and raises awareness	42
Watch and wait for rectal cancer: towards data-informed surveillance	42
Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled,	42
Spleen stiffness in portal hypertension algorithms: the next advance	42
The liver–brain axis in metabolic dysfunction-associated steatotic liver disease	42
Diet or optimised medical therapy for people with irritable bowel syndrome	42
Standardising early liver transplantation for severe alcohol-related hepatitis	41
A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised contro	41
Hepatitis C virus in sub-Saharan Africa: a long road to elimination	40
Correction to Lancet Gastroenterol Hepatol 2025; 10: 715–25	39
Fine-tuning the gut ecosystem: the current landscape and outlook of artificial microbiome therapeutics	39
Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	38
Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial	38
Pre-emptive TIPS for gastric variceal bleeding in patients with cirrhosis (GAVAPROSEC): an open-label randomised clinical trial	38
Addressing Africa's marginalisation in hepatocellular carcinoma clinical trials	37
The role of [18F]FDG and [18F]FCH PET-CT in hepatocellular carcinoma with cirrhosis	37
World Hepatitis Day 2025: elimination at a critical juncture	37
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial	36
Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD	36
Elimination of hepatitis B requires recognition of catastrophic costs for patients and their families	36
Research in Brief	35

Combination locoregional and systemic therapies in hepatocellular carcinoma	35
An open letter to Gavi: hepatitis B birth dose vaccine can't wait	35
A coordinated multipronged attack: integrated care is the future for gastroenterology	35
Research in Brief	35
The International Liver Congress 2022	34
Inequities in alcohol-related harm in the Philippines	34
Polypoid lesions in the stomach and the colon: Cronkhite-Canada syndrome	34
Research in Brief	34
Oncological safety of laparoscopic surgery for low rectal cancer	33
More is not always better for novel hepatitis B therapies	33
Accelerating point-of-care HCV viral load testing	33
Correction to Lancet Gastroenterol Hepatol 2021; 6: 784–92	33
The lottery of primary care for liver disease	33
Time for a treat all approach for hepatitis B	32
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from	32
Is the attenuated humoral response to COVID-19 vaccination in anti-TNF users relevant?	32
Launch of the International Living Donor Liver Transplantation Outcomes Registry	32
Infliximab rescue therapy in acute severe ulcerative colitis: more does not equal better	31
Inclusion of patients with isolated ulcerative proctitis in clinical trials	31
SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy	31
Endoscopic interventions for stricturing Crohn's disease	30
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study	29
MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomise	29
Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions	28
Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial	28
Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study	28
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis	28
No accident: the UK infected blood scandal	27
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study	27
The Liver Meeting 2023	27
The case for reducing the use of diagnostic upper and lower gastrointestinal endoscopy	27
Research in Brief	27
Challenging stigma around alcohol misuse	26
Séverine Vermeire: advancing patient-centred research in IBD	26
Stringent criteria for withdrawal of biologics in ulcerative colitis – Authors' reply	26
Ranking treatments in the network meta-analysis should consider the certainty of evidence – Authors' reply	26
Peroral endoscopic myotomy versus pneumatic dilation in treatment-naive patients with achalasia – Authors' reply	26
17th Congress of ECCO	26
Vedolizumab in paediatric IBD: a huge step forward but not there yet	26
Psychological therapies in inflammatory bowel disease	25
Chronic Boom	25
A new chapter in the campaign to eliminate viral hepatitis?	25
Gastric examination by guided capsule endoscopy: a new era	25
Haematopoietic stem-cell transplantation in Crohn's disease	24
Lessons from a trial of colesevelam for bile acid diarrhoea	24
Oral faecal microbiota transplantation in ulcerative colitis	23
Robotic pancreatoduodenectomy: preparing for the future	23
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial	23
Hypovolaemic phlebotomy to reduce the need for perioperative transfusion: a price worth paying?	23
Top ten research priorities for alcohol use disorder and alcohol-related liver disease: results of a multistakeholder research priority setting partnership	23
Tackling obesity: drugs are only part of the solution	23
Local ablation in pancreatic cancer: some answers and more questions	23
Retina and liver fibrosis screening for patients with type 2 diabetes	22
Terlipressin for hepatorenal syndrome: opportunities and challenges	22
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated rand	22
The urgent need to end hepatitis B stigma and discrimination	22
Comparison of trends in early-onset colorectal cancer in North America and Europe	21
Global epidemiology of acute kidney injury in hospitalised patients with decompensated cirrhosis: the International Club of Ascites GLOBAL AKI prospective, multicentre, cohort study	21
Implementing metabolic dysfunction-associated steatotic liver disease guidelines in patients with type 2 diabetes	21
Effect of prophylactic endoscopic clip placement on clinically significant post-endoscopic mucosal resection bleeding in the right colon: a single-centre, randomised controlled trial	21
Metachronous colorectal cancer risk according to Lynch syndrome pathogenic variant after extensive versus partial colectomy in the Netherlands: a retrospective cohort study	21
A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia	20
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based th	20
A call for advocacy and patient voice to eliminate hepatitis B virus infection	20
Cultural competence in the delivery of nutrition and symptom care in irritable bowel syndrome	19
Prophylactic abdominal drainage after distal pancreatectomy: really unnecessary? – Author's reply	18
Are all post-ESWL pancreatitis events clinically significant?	18
Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial	18
Research in Brief	18
Research in Brief	18
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial	18
Diet or optimised medical therapy for people with irritable bowel syndrome	18
Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial	18
Variceal embolisation plus TIPS for variceal bleeding	17
Financing viral hepatitis: catalysing action for impact	17
An important step towards the long-term treatment of eosinophilic oesophagitis	17
Expression of concern—Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre random	17
Liver disease admissions in the UK are increasing, urgently needing local and national solutions	17
Non-coeliac gluten sensitivity: from Salerno to Rome	17
Prophylactic abdominal drainage after distal pancreatectomy: really unnecessary?	17
Septic arthritis: a presentation of Crohn's disease	17
Minimising the risk of monkeypox virus transmission during faecal microbiota transplantation: recommendations from a European expert panel	16
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials	16
Africa CDC's viral hepatitis prevention and control programme: a continental initiative to support elimination programmes	16
No easy way out: blocking lymphocyte egress by the S1P1 receptor 1 modulator tamuzimod in ulcerative colitis	16
NAFLD prevalence and severity in overweight and obese populations	15
Intraoperative fluorescence angiography with indocyanine green to prevent anastomotic leak in rectal cancer surgery (IntAct): an unblinded randomised controlled trial	15
Antibiotic treatment versus appendicectomy for acute appendicitis in adults: an individual patient data meta-analysis	15
Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions	14
A path to global cirrhosis health equity	14
Single CT colonography versus three rounds of faecal immunochemical test for population-based screening of colorectal cancer (SAVE): a randomised controlled trial	14
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial	14
An Indigenous First Nations perspective on liver health	14
Pathogens don't respect politicians: US federal disruption poses a new threat to global public health	13
Targeting type 2 immune responses to treat eosinophilic gastritis	13